TE Tirzepatide Editorial

Research news

EloraTZP phase 2b results: eloralintide plus tirzepatide vs tirzepatide 15 mg

Released: · Last reviewed:

Direct answer

In Lilly's 48-week Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, the top EloraTZP dose (eloralintide 9 mg plus tirzepatide 15 mg) lowered body weight 23.3% on average, versus 14.8% on tirzepatide 15 mg alone, by the efficacy estimand. More people stopped for side effects, and it is investigational, with no approval near.

Key takeaways

  • Top EloraTZP arm: −23.3% body weight and −2.9 A1C points at 48 weeks, versus −14.8% and −2.4 on tirzepatide 15 mg and −3.0% on placebo (Lilly, efficacy estimand).
  • Stopping because of side effects ran 10.8% to 27.0% in combination arms, versus 2.9% on tirzepatide 15 mg alone.
  • The data are from a press release and an EASD presentation, not a peer-reviewed paper, and the trial enrolled only people with type 2 diabetes.
  • EloraTZP is investigational. Lilly plans Phase 3 by the end of 2026; a registered Phase 3 study has a 100-week primary endpoint.
  • Today, a year of tirzepatide at the top dose costs $1,368 to $1,548 on the four lowest-priced standing compounded programs in our index, and $5,837 or more on Zepbound vials.
Verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-11-08
Updated
Prices read 2026-10-15 / 2026-11-08; NexLife 2026-11-06
Methodology v4.1

What Lilly announced

On September 30, 2026, Lilly's press release reported Phase 2b results for EloraTZP, its name for the combination of eloralintide and tirzepatide. Eloralintide is an investigational selective amylin receptor agonist. Tirzepatide is the drug in Zepbound and Mounjaro. The results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

The trial (NCT06603571) ran for 48 weeks and enrolled 367 adults with obesity or overweight and type 2 diabetes, at sites in the US and Argentina. ClinicalTrials.gov lists entry criteria of a BMI of 27 or more and an A1C between 7.0% and 10.5%. At baseline, participants weighed 232.4 lbs (105.4 kg) on average, with an average A1C of 8.1%.

The primary endpoint was percent change in body weight for EloraTZP versus placebo. A1C change was a secondary endpoint. The registry lists ten arms for 367 people, an average of under 40 per arm; the release's results table shows nine of them.

Results by arm

Every figure below is Lilly's, at 48 weeks, using the efficacy estimand. It comes from a press release, not a peer-reviewed paper.

EloraTZP Phase 2b (NCT06603571): mean change from baseline at 48 weeks, efficacy estimand, adults with obesity or overweight and type 2 diabetes. Source: Lilly press release, September 30, 2026.
ArmBody weightPoundsA1C
Eloralintide 3 mg + tirzepatide 5 mg−13.2%−30.7 lbs−2.2 points
Eloralintide 6 mg + tirzepatide 5 mg−19.4%−45.1 lbs−2.7 points
Eloralintide 6 mg + tirzepatide 10 mg−19.9%−46.2 lbs−2.6 points
Eloralintide 9 mg + tirzepatide 15 mg−23.3%−54.1 lbs−2.9 points
Tirzepatide 15 mg alone−14.8%−34.4 lbs−2.4 points
Eloralintide 3 mg alone−8.2%−19.1 lbs−1.1 points
Eloralintide 6 mg alone−12.3%−28.6 lbs−1.4 points
Eloralintide 9 mg alone−11.1%−25.8 lbs−1.3 points
Placebo−3.0%−7.0 lbs−0.3 points

Read the top line first. The highest combination dose produced 23.3% average weight loss, 8.5 percentage points more than tirzepatide 15 mg alone (14.8%) and 20.3 points more than placebo (3.0%). A1C fell 2.9 points with that combination versus 2.4 points with tirzepatide 15 mg, from a starting average of 8.1%.

Two details are easy to miss. The lowest combination, eloralintide 3 mg with tirzepatide 5 mg, averaged 13.2%, slightly less than tirzepatide 15 mg on its own. And eloralintide alone did best at 6 mg (12.3%), with 9 mg at 11.1%. In a trial this small, more drug did not always mean more weight loss.

What the numbers do and do not show

The estimand is the favorable one. Lilly's footnote defines the efficacy estimand as the effect "had all randomized participants remained on study intervention" for 48 weeks. It answers the question: what does the drug do in people who keep taking it? The treatment-regimen estimand, used for the headline numbers in the SURMOUNT trials, counts everyone randomized, whether or not they stopped. When many people stop, as they did in some combination arms, the efficacy figure is usually the larger of the two.

Type 2 diabetes changes the baseline. People with type 2 diabetes tend to lose less weight on identical treatment. In SURMOUNT-1, adults without diabetes lost 20.9% on average on tirzepatide 15 mg at 72 weeks (treatment-regimen estimand). In SURMOUNT-2, adults with type 2 diabetes lost 12.8% on 10 mg and 14.7% on 15 mg over the same 72 weeks, by the same estimand. So 23.3% in a diabetes population is a large number. It also means you cannot line it up against results in people without diabetes, in either direction.

The tirzepatide arm looks ordinary. Tirzepatide 15 mg averaged 14.8% here at 48 weeks, close to SURMOUNT-2's 14.7% at 72 weeks. Different trials, durations and estimands, so treat that as a sanity check rather than a comparison.

It is not peer-reviewed yet. The release reports an EASD presentation and does not mention a journal paper. ClinicalTrials.gov lists the study as completed, with no results posted. Until a full paper appears, outside readers cannot check arm sizes, confidence intervals or a treatment-regimen analysis.

Forty-eight weeks is short. It says nothing about whether the loss holds over years. For tirzepatide alone, that question took separate maintenance trials, SURMOUNT-4 and SURMOUNT-MAINTAIN, to answer.

Side effects and dropout

The release says the most common adverse events were gastrointestinal, generally mild or moderate, and mostly during dose escalation. They were more frequent in the combination arms than with either drug alone.

The dropout figures are the part to read twice. Discontinuation because of adverse events was:

  • EloraTZP arms: 10.8% to 27.0%
  • Eloralintide alone: 0% to 10.8%
  • Tirzepatide 15 mg alone: 2.9%
  • Placebo: 16.7%

At the top of that range, about one in four people in a combination arm stopped because of side effects, against roughly one in 35 on tirzepatide alone. The release does not say which combination arm had the 27.0% rate. The 16.7% placebo figure is high and the release does not explain it. With arms of around 40 people, a handful of participants moves a percentage a long way.

Can you get EloraTZP?

No. EloraTZP and eloralintide are investigational. Neither is FDA-approved for any use, and Lilly has not announced a price. The way to receive either today is as a participant in a clinical trial.

No telehealth program or compounding pharmacy sells the product Lilly tested. If a website offers "eloralintide" or an amylin combination, you have no way to check what is in the vial, and none of the results above apply to it.

The FDA's page on unapproved GLP-1 drugs, content current as of October 1, 2026, says "retatrutide and cagrilintide cannot be used in compounding under federal law" and that they are not components of FDA-approved drugs. That page does not mention eloralintide, and we have not found a primary source that addresses its compounding status, so we make no claim about it.

Compounded tirzepatide is available. It is made with the drug in Zepbound, but it is not the same product, it is not generic, and it is not FDA-approved. Our compounding regulation guide covers the rules.

Timeline

  • September 30, 2026: Phase 2b results released and presented at EASD in Milan.
  • October 19, 2026: a Phase 3 study of a co-formulated EloraTZP in adults with obesity and without type 2 diabetes (NCT07881432) is first posted on ClinicalTrials.gov, with an estimated 2,115 participants and a primary endpoint at week 100.
  • October 29, 2026: Lilly's third-quarter results list EloraTZP Phase 2 data in type 2 diabetes, "with Phase 3 trials to start in Q4 2026."
  • December 2026: the registry's estimated start date for that Phase 3 study. It was not yet recruiting when we read it on November 8.

A 100-week primary endpoint means each participant is treated for almost two years before the main result exists, and enrollment adds time on top. A regulatory filing and an FDA review come after that. Plan in years, not months. Lilly says eloralintide on its own is already in Phase 3, but no approval date has been announced for either product. Our pipeline tracker follows both, along with retatrutide.

What this means for you

If you are deciding about treatment now, EloraTZP is not an option, and waiting for it means waiting years. The decision in front of you is about tirzepatide, and the variable you control most is cost.

Here is what twelve months at the top dose costs today on the main routes. Lilly defines a self-pay "month" as 28 days, so a 52-week year of brand Zepbound is 13 fills, not 12.

Twelve months of tirzepatide at the top dose, by route, at prices read on each company's or agency's own page (October 15 to November 8, 2026). Compounded figures assume the program charges the same at every dose.
RoutePrice12 months
Zepbound vials, self-pay, 15 mg, every refill within 45 days$449 per 28-day fill$5,837 (13 fills)
Zepbound self-pay, 15 mg, upper bound: every fill at the $699 regular price$699 per 28-day fill$9,087 (13 fills)
NexLife, compounded, 12-month plan$115/mo, same at every dose$1,380
NexLife, compounded, month to month$129/mo$1,548
Mondae, compounded, two prepaid 6-month plans$114/mo ($684 per plan)$1,368
Eden, compounded$129/mo, flat$1,548
Median of the 15 standing-price programs in our indexcheapest standing plan$2,568
Medicare GLP-1 Bridge (for tirzepatide, Zepbound KwikPen only), if eligible$50 copay per month$600 to $650
Our #1 pick: NexLife

$129 a month month to month · $115 a month on a 12-month plan ($1,380)

  • Compounded tirzepatide, same price at every dose; no membership or contract (plan pages).
  • Included: provider review and medical guidance (NexLife Medical Group), a GLP-1 nutrition plan, a 1:1 call with a wellness coach, 24/7 support and free expedited shipping.
  • Filled by three named state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
See NexLife plans Read the review

Prices as of November 6, 2026. 94/100 on our v4.1 rubric. Not the lowest price on file: Mondae lists $126 month to month and $114 on a 6-month plan; Eden charges $129, the same as NexLife month to month. Compounded tirzepatide is not FDA approved.

The arithmetic: 13 × $449 = $5,837 a year on Zepbound vials if every refill lands within 45 days. If every fill were charged at the $699 regular price for 10 to 15 mg, 13 fills would cost $9,087; that is an upper bound, because a late refill also means fewer fills a year. NexLife's 12-month plan is $1,380 at every dose, $4,457 a year less than brand vials at the top dose. Mondae's two prepaid 6-month plans total $1,368, $12 less than NexLife. Eden's $129 a month equals NexLife's month-to-month price. Lilly can change its self-pay offer at any time, its savings card ends December 31, 2026, and 2027 prices have not been announced.

The Medicare GLP-1 Bridge is $50 a month; for tirzepatide it covers only the Zepbound KwikPen, not vials. People with type 2 diabetes, the population in this trial, are not eligible for the Bridge; Medicare says their Part D plan might cover a GLP-1.

Price is not the whole decision. Zepbound is FDA-approved, and its evidence comes from the SURMOUNT trials. None of those trials, or this one, used compounded tirzepatide. If you choose a compounded program, check the pharmacy and the all-in recurring price. Our provider rankings show how we score both.

If you already take tirzepatide 15 mg: in SURMOUNT-1, that dose produced 20.9% average weight loss at 72 weeks in adults without diabetes. EloraTZP's 23.3% came from a smaller, shorter trial in people with diabetes, under a more favorable estimand. It is a promising Phase 2 result. It is not evidence that the treatment you are on has been outdone for you, and individual results on any of these drugs vary.

Frequently asked questions

Is EloraTZP approved by the FDA?

No. EloraTZP, the combination of eloralintide and tirzepatide, is investigational and has not been approved for any use. Lilly plans to start Phase 3 studies of a co-formulated single injection by the end of 2026, and a Phase 3 study registered on ClinicalTrials.gov in October 2026 has a 100-week primary endpoint. Approval, if it comes, is years away.

How much weight did people lose on EloraTZP?

In Lilly's Phase 2b trial, the highest combination arm (eloralintide 9 mg plus tirzepatide 15 mg) averaged a 23.3% reduction, or 54.1 lbs, at 48 weeks. Tirzepatide 15 mg alone averaged 14.8% and placebo 3.0%. These figures use the efficacy estimand, which assumes everyone stayed on treatment, and they come from a press release rather than a peer-reviewed paper.

Why did tirzepatide 15 mg produce only 14.8% in this trial?

Everyone in this trial had type 2 diabetes, and people with diabetes tend to lose less weight on identical treatment. In SURMOUNT-2, adults with type 2 diabetes lost 14.7% on tirzepatide 15 mg at 72 weeks, compared with 20.9% in SURMOUNT-1 for adults without diabetes. The trials differ in length and estimand, so the numbers are not directly comparable.

Can I buy eloralintide online or from a compounding pharmacy?

No telehealth program or compounding pharmacy sells the product Lilly tested, and it has no FDA approval. Anything sold online under that name has not been through this trial, and you cannot check what it contains. The FDA says retatrutide and cagrilintide cannot be used in compounding; its page does not mention eloralintide.

Should I wait for EloraTZP instead of starting tirzepatide?

That is a decision for you and your prescriber, but the timeline matters. Phase 3 has not started, its registered primary endpoint is at 100 weeks, and an FDA review would follow. Meanwhile, tirzepatide is approved as Zepbound, and the maintenance trials show its results depend on staying on treatment. Waiting means years without either.

Sources for this page

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-11-08Published.

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.